Imperial College London


Faculty of MedicineDepartment of Surgery & Cancer

Clinical Senior Lecturer in Medical Oncology



+44 (0)20 7594 2806l.kenny




137ICTEM buildingHammersmith Campus





DirecTOR EARLY PHASE CLINICAL TRIALS (CANCER), Clinical Senior Lecturer,  Imperial College London and Consultant Medical Oncologist, Imperial College NHS Healthcare Trust.

Dr Laura Kenny trained in Medicine in Queen's University Belfast, after completion of junior medical training she chose to persue a career in medical oncology. Following initial registrar training, she moved to London to study for a PhD in translational molecular imaging in the Cyclotron Building, Imperial College London. She was awarded a Westminster Medical School Oncology Trustee's fellowship.Her research focused on the use of novel PET radiotracers for studying proliferation (fluorothymidine (FLT)), angiogenesis (fluciclatide (AH-111585), and choline metabolism in breast cancer patients. Her work has been published in Cancer Research, Clinical Cancer Research, the Journal of Nuclear Medicine, and the European Journal of Molecular Imaging and Nuclear Medicine.

Laura was awarded a prestigious NIHR/MRC clinician scientist fellowship  in 2010, the aim of her project was to establish new methods for defining the imaging phenotype in patients in vivo which will help predict drug resistance and drug sensitivity at early timepoints to established and novel cancer therapeutic agents.  Her research has been recognised by the American Association of Cancer Research (Young Investigator Award), American Society of Clinical Oncology (Merit Award), British Cancer Research Meeting (Translational Research Award), and she also won the McElwain prize. Laura has been invited to give international lectures about her research.

More recently Laura was appointed as Director of  Early Phase Clinical Trials in Cancer, where her aim is to expedite clinical drug development with novel approaches to clinical trials. She was also awarded an MRC DPFS project grant to study a new Affibody probe which will target her2 expression in breast cancer, this will be a first in man study and involves collaboration with 4 leading oncology centres in the UK. Her clinical practice is based at Charing Cross and Hammersmith Hospitals (part of Imperial College  Healthcare NHS Trust).



Coombes RC, Howell S, Lord SR, et al., 2023, Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib., Nature Communications, Vol:14, ISSN:2041-1723, Pages:1-1

Charles Coombes R, Howell S, Lord SR, et al., 2023, Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib, Nature Communications, Vol:14, ISSN:2041-1723

Aboagye E, Aravind P, Popat S, et al., 2023, A subset of non-small cell lung cancer patients treated with pemetrexed show 18f-fluorothymidine ‘flare’ on positron emission tomography, Cancers, Vol:15, ISSN:2072-6694, Pages:1-14

Fleming B, Edison P, Kenny L, 2023, Cognitive impairment after cancer treatment: mechanisms, clinical characterization, and management, Bmj-british Medical Journal, Vol:380, ISSN:0959-535X

Kenny L, Hyland P, Cloitre M, et al., 2023, Factor Structure of the Shortened Six-Item Version of the de Jong Gierveld Loneliness Scale (DJGLS-6) A Systematic Review and Testing Factor Models in a Nationally Representative Sample, European Journal of Mental Health, Vol:18, ISSN:1788-4934

More Publications